Get the Stockscreener App
17.08
5.56%
0.90
After Hours:
17.64
0.56
+3.28%
Ideaya Biosciences Inc stock is traded at $17.08, with a volume of 1.66M.
It is up +5.56% in the last 24 hours and down -10.72% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
See More
Previous Close:
$16.18
Open:
$16.07
24h Volume:
1.66M
Relative Volume:
1.56
Market Cap:
$1.50B
Revenue:
$23.38M
Net Income/Loss:
$-155.22M
P/E Ratio:
-7.7991
EPS:
-2.19
Net Cash Flow:
$-134.36M
1W Performance:
+8.31%
1M Performance:
-10.72%
6M Performance:
-44.35%
1Y Performance:
-57.48%
1-Day Range:
$16.07
$17.13
1-Week Range:
$15.33
$17.30
52-Week Range:
$13.45
$44.42
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
17.08 | 1.50B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Initiated | Stephens | Overweight |
| Nov-05-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Mar-08-24 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | SVB Securities | Outperform |
| May-24-23 | Initiated | Goldman | Buy |
| Apr-24-23 | Upgrade | Stifel | Hold → Buy |
| Mar-23-23 | Initiated | Berenberg | Buy |
| Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-28-22 | Initiated | CapitalOne | Overweight |
| Oct-27-22 | Initiated | Citigroup | Buy |
| Aug-15-22 | Downgrade | Stifel | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-10-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-11-21 | Initiated | Guggenheim | Buy |
| Oct-07-20 | Initiated | Wedbush | Outperform |
| Sep-01-20 | Initiated | Northland Capital | Outperform |
| Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-06-20 | Initiated | H.C. Wainwright | Buy |
| Mar-13-20 | Initiated | ROTH Capital | Buy |
| Oct-17-19 | Initiated | Oppenheimer | Outperform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Jun-17-19 | Initiated | Citigroup | Buy |
| Jun-17-19 | Initiated | JP Morgan | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC (PR Newswire) - Aktiellt
JPMorgan Chase & Co. Has $7.06 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
(IDYA) Trading Report - news.stocktradersdaily.com
Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later - Seeking Alpha
IDEAYA advances darovasertib in uveal melanoma trial By Investing.com - Investing.com Nigeria
Ideaya Biosciences Completes Phase 3 Trial Design Meetings With FDA; Shares Up Pre-Bell - marketscreener.com
IDEAYA advances darovasertib in uveal melanoma trial - Investing.com Australia
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma - BioSpace
Ideaya Biosciences Announces Successful FDA Type D Meeting for Darovasertib - MarketScreener
Major FDA Breakthrough: IDEAYA's Eye-Saving Cancer Drug Advances to Phase 3 Trial - Stock Titan
Geode Capital Management LLC Acquires 43,226 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Ideaya Biosciences (IDYA) Launches Expanded Phase 1/2 Trial for IDE397 in Cancer Treatment | GILD Stock News - GuruFocus
Ideaya Biosciences Begins Phase 1/2 Expansion in Urothelial Cancer Treatment Trial in Combination With Gilead's Trodelvy - marketscreener.com
IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and - GuruFocus
Ideaya Biosciences Announces Phase 1/2 Expansion For Ide397 And Trodelvy® Combination In Mtap-Deletion Urothelial Cancer - marketscreener.com
IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer – Company AnnouncementFT.com - Financial Times
IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer - PR Newswire
Indo-Asian News Service - Indo-Asian News Service (IANS)
Norges Bank Purchases Shares of 520,810 IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - The AM Reporter
Vanguard Group Inc. Has $130.51 Million Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Ideaya stock hits 52-week low at $14.09 amid market challenges By Investing.com - Investing.com South Africa
Ideaya stock hits 52-week low at $14.09 amid market challenges - Investing.com Australia
IDEAYA to Participate in Upcoming September 2020 Investor Relations Events - BioSpace
KLP Kapitalforvaltning AS Makes New $383,000 Investment in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences announces board change and new advisory role By Investing.com - Investing.com South Africa
IDEAYA Biosciences announces board change and new advisory role - Investing.com
Why Ideaya Biosciences Is Down Despite Many Positives (NASDAQ:IDYA) - Seeking Alpha
IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events - BioSpace
Where are the Opportunities in (IDYA) - news.stocktradersdaily.com
IDEAYA's Eye Cancer Therapy Receives Breakthrough Therapy Designation From FDA - MarketScreener
IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation For Darovasertib Monotherapy In Neoadjuvant Uveal Melanoma - MarketScreener
Revolutionary Eye Cancer Drug Achieves FDA Breakthrough Status: 82% Tumor Shrinkage Rate - Stock Titan
IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma - The Malaysian Reserve
Ideaya Biosciences stock hits 52-week low at $16.95 By Investing.com - Investing.com South Africa
Ideaya Biosciences stock hits 52-week low at $16.95 - Investing.com
IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
IDEAYA Awards $306K Worth of Stock Options to Strategic New Hire - Stock Titan
IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor - Marketscreener.com
(IDYA) Technical Pivots with Risk Controls - Stock Traders Daily
Ideaya Biosciences stock hits 52-week low at $17.28 By Investing.com - Investing.com Australia
Ideaya Biosciences stock hits 52-week low at $17.28 - Investing.com
IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up – What’s Next? - Defense World
IDEAYA Announces Further Gilead Sciences Clinical Study Collabor - GuruFocus.com
IDEAYA Biosciences, Inc. (IDYA) Partners with ATTMOS for AI-Driven Drug Discovery Platform - Insider Monkey
Top 10 AI Trending News on Wall Street - Insider Monkey
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets - BioSpace
IDEAYA Biosciences Partners With ATTMOS To Advance AI/ML-Driven Oncology Drug Discovery - Nasdaq
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accele - GuruFocus.com
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):